| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
United Therapeutics Corporation (NASDAQ: UTHR)
UTHR Technical Analysis
4
| As on 9th Jun 2023 UTHR SHARE Price closed @ 228.49 and we RECOMMEND Buy for LONG-TERM with Stoploss of 211.71 & Strong Buy for SHORT-TERM with Stoploss of 197.69 we also expect STOCK to react on Following IMPORTANT LEVELS. |
UTHRSHARE Price
| Open | 226.12 | Change | Price | % |
| High | 229.32 | 1 Day | 1.99 | 0.88 |
| Low | 224.64 | 1 Week | 18.75 | 8.94 |
| Close | 228.49 | 1 Month | 0.78 | 0.34 |
| Volume | 269164 | 1 Year | 23.37 | 11.39 |
| 52 Week High 280.43 | 52 Week Low 166.16 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| UTHR Daily Charts |
UTHR Intraday Charts |
Whats New @ Bazaartrend |
UTHR Free Analysis |
|
|
UTHR Important Levels Intraday
| RESISTANCE | 237.51 |
| RESISTANCE | 234.62 |
| RESISTANCE | 232.83 |
| RESISTANCE | 231.04 |
| SUPPORT | 225.94 |
| SUPPORT | 224.15 |
| SUPPORT | 222.36 |
| SUPPORT | 219.47 |
UTHR Forecast April 2024
| 4th UP Forecast | 278.57 |
| 3rd UP Forecast | 262.51 |
| 2nd UP Forecast | 252.58 |
| 1st UP Forecast | 242.65 |
| 1st DOWN Forecast | 214.33 |
| 2nd DOWN Forecast | 204.4 |
| 3rd DOWN Forecast | 194.47 |
| 4th DOWN Forecast | 178.41 |
UTHR Weekly Forecast
| 4th UP Forecast | 265.72 |
| 3rd UP Forecast | 253.78 |
| 2nd UP Forecast | 246.40 |
| 1st UP Forecast | 239.02 |
| 1st DOWN Forecast | 217.96 |
| 2nd DOWN Forecast | 210.58 |
| 3rd DOWN Forecast | 203.20 |
| 4th DOWN Forecast | 191.26 |
UTHR Forecast2024
| 4th UP Forecast | 468.81 |
| 3rd UP Forecast | 391.74 |
| 2nd UP Forecast | 344.1 |
| 1st UP Forecast | 296.46 |
| 1st DOWN Forecast | 160.52 |
| 2nd DOWN Forecast | 112.88 |
| 3rd DOWN Forecast | 65.24 |
| 4th DOWN Forecast | -11.83 |
United Therapeutics Corporation ( NASDAQ USA Symbol : UTHR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
UTHR Business Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. Address: 1040 Spring Street, Silver Spring, MD, United States, 20910
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service